-- 通用电气医疗技术公司（GEHC）周三公布了第一季度调整后每股收益为0.99美元，低于去年同期的1.01美元。 FactSet调查的分析师此前预期为1.05美元。 截至3月31日的第一季度，公司营收为51.3亿美元，高于去年同期的47.8亿美元。 FactSet调查的分析师此前预期为50.3亿美元。 公司目前预计2026年调整后每股收益为4.80美元至5美元，低于此前预期的4.95美元至5.15美元。FactSet调查的分析师此前预期为5.06美元。 与此同时，通用电气医疗重申了全年3%至4%的有机营收增长预期。FactSet调查的分析师此前预期为217.1亿美元。 该公司股价在周三盘前交易中下跌超过6%。
Price: $64.12, Change: $-4.38, Percent Change: -6.39%
Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.
Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.